Iscover (Clopidogrel)

Clopidogrel irreversibly blocks the platelet P2Y12 ADP receptor, preventing ADP‑mediated activation of the glycoprotein IIb/IIIa complex. This inhibition stops platelets from aggregating, thereby reducing the formation of blood clots that can cause cardiovascular events.

The dosage of clopidogrel is determined by the prescribing clinician based on the patient’s medical condition, renal function, and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

Clopidogrel is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It should be used during pregnancy or lactation only if the potential benefits justify the possible risks, and under medical supervision.

To request Iscover, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Clopidogrel differs from aspirin by selectively targeting the P2Y12 receptor rather than cyclooxygenase‑1. Compared with newer agents like ticagrelor, clopidogrel has a longer activation period and may be less potent, but it is often chosen for its established safety profile and lower cost.

Iscover tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain stability and potency.

Iscover is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include severe or uncontrolled bleeding, such as intracranial hemorrhage, gastrointestinal bleeding, and rare blood disorders like thrombocytopenia or thrombotic thrombocytopenic purpura. Patients should seek immediate medical attention if they experience unusual bruising, blood in stool, or severe headache.

Clopidogrel is contraindicated in individuals with active pathological bleeding, known hypersensitivity to clopidogrel or any component of the formulation, and in patients with severe hepatic impairment. It should also be used with caution in those with a history of hemorrhagic stroke.